USP <797> and compounded peptide injections: what consumers can verify

01

What USP <797> covers

The United States Pharmacopeia describes General Chapter <797> as minimum standards for compounded sterile preparations used in humans and animals. Its scope includes combining, admixing, diluting, pooling, reconstituting, repackaging, or otherwise altering a drug product or bulk substance to create a sterile preparation.

The chapter addresses systems intended to reduce contamination, concentration errors, and other quality failures. Topics include personnel training and qualification, hand hygiene and garbing, facilities and engineering controls, environmental monitoring, cleaning, disinfection, sterilization, release testing, documentation, storage, transport, and beyond-use dates.

A peptide vial intended for injection can raise sterile-compounding questions, but the chapter is not a do-it-yourself reconstitution guide. Consumers should not use a summary of <797> to mix, transfer, divide, or inject a product. Preparation and administration questions belong with the dispensing pharmacist and licensed clinician.

02

Official standards and enforcement are different roles

USP’s December 2023 FAQ states that the revision published November 1, 2022 became official November 1, 2023. It also explains that the applicable regulatory jurisdiction is responsible for ensuring compliance and may use a different implementation date. USP itself does not enforce the chapter.

State boards of pharmacy, FDA, accreditation organizations, and other authorities have different jurisdiction and scopes. Which rules apply can depend on whether the compounder is a state-licensed pharmacy operating under section 503A, an FDA-registered outsourcing facility under section 503B, a hospital, or another entity.

Therefore, compliant with USP <797> is not a self-proving legal conclusion. Ask which jurisdiction adopted which version, the facility type, the most recent license and inspection record, and whether any finding remains open. A marketing badge without those details is only a claim.

03

What a USP <797> claim cannot prove

The chapter does not make a compounded peptide FDA-approved. FDA states that compounded drugs do not undergo its premarket review for safety, effectiveness, or quality. A facility’s effort to follow sterile-compounding standards and a drug application approval are fundamentally different processes.

The claim also does not establish that a particular peptide is permitted as a bulk substance, supported for a marketed use, free from every impurity, stable for the assigned beyond-use date, or correctly handled after dispensing. Sterility is only one quality dimension; identity, strength, purity, endotoxins, container integrity, labeling, shipping, and storage can also matter.

Finally, compliance does not show that an injection is appropriate for a person. A clean-room process cannot repair weak clinical evidence, an unapproved product claim, an invalid prescription, or inadequate medical follow-up.

04

Why sterile technique matters after the pharmacy

Quality controls can be undermined by later handling. CDC’s injection-safety guidance identifies contamination risks from reusing needles or syringes, entering medication containers with used equipment, preparing medicine near contaminated materials, and sharing single-dose containers across patients.

CDC recommends a sterile, single-use needle and syringe for each injection and prefers single-dose vials when possible, especially when medicine might otherwise be used for multiple patients. These are infection-prevention principles, not peptide dosing instructions.

Consumers should receive clear written instructions for the exact dispensed product and a way to reach a pharmacist or clinician. A clinic that ships an injectable without an intact label, storage directions, administration support, or a sharps plan has left important safety questions unanswered.

05

How to investigate a pharmacy’s sterile-compounding claim

Begin with the legal name and physical location on the patient label. Verify the state pharmacy license and facility type. If the provider says the pharmacy is a 503B outsourcing facility, match it to FDA’s current registration information; do not infer 503B status from a logo or the word outsourcing.

Review available inspection records, Form 483 observations, warning letters, recalls, disciplinary records, and any accreditation scope. An observation is not a final violation finding, and a lack of a public record is not proof that every batch is problem free. Match every record to the correct facility and date.

Ask how the pharmacy supports its assigned beyond-use date, handles temperature-controlled shipping, investigates excursions or visible damage, and reports complaints. The goal is not to audit a clean room from home. It is to test whether the provider can identify the responsible pharmacy and answer basic product-level questions without vague assurances.

• →Exact pharmacy name and location
• →503A or 503B pathway
• →Applicable state license
• →USP <797> version and jurisdiction
• →Current inspection and recall context
• →Product label, lot, and beyond-use date
• →Storage, shipping, complaint, and adverse-event process

06

Warning signs in peptide-provider marketing

Be cautious when a clinic says USP compliant therefore FDA approved, pharmaceutical grade, guaranteed sterile, or safer than an approved product. Those conclusions do not follow from the chapter. FDA also cautions that poor-quality compounded drugs can contain contamination or the wrong amount of active ingredient and cause serious injury or death.

Other warning signs include refusing to name the pharmacy before payment, using the same generic storage instructions for every peptide, treating a beyond-use date as an expiration date supported by FDA, or presenting a single sterility certificate as a guarantee for future lots. A certificate should be matched to the actual batch and understood within the pharmacy’s complete quality system.

If a vial is damaged, discolored, mislabeled, warm when it should be cold, or associated with an unexpected reaction, contact the dispensing pharmacy and clinician promptly. Urgent symptoms require appropriate medical care. The provider should also explain how to report a product problem to FDA MedWatch without discouraging a report.